Vascular Complications After Transcatheter Aortic Valve Replacement

Abstract

Major VC were frequent after TF-TAVR in the PARTNER trial using first-generation devices and were associated with high mortality. However, the incidence and impact of major VC on 1-year mortality decreased with lower-risk populations.

Long-Term Outcomes of Inoperable Patients With Aortic Stenosis Randomly Assigned to Transcatheter Aortic Valve Replacement or Standard Therapy

“…9,10,14,15 Postprocedural complications such as aortic regurgitation, stroke, acute kidney injury, and vascular complications have also been associated with worsening long-term outcomes. 4,[16][17][18] Attempts to investigate whether surgical risk scores, including Euroscore or STS score, could predict poor long-term outcomes have yielded conflicting results. 9,19,20 In our analysis, mortality was higher in patients with multiple comorbidities, as evidenced by higher STS scores.…”

Procedural Results and Clinical Outcomes of Transcatheter Aortic Valve Implantation in Switzerland

“…27 With the first generation balloonexpandable THV, major vascular complications occurred in 28 has resulted in decreased vascular complications. In our study, major and minor vascular complications were significantly lower in S3 compared with XT patients.…”

Factors Associated With Vascular Complications in Patients Undergoing Balloon-Expandable Transfemoral Transcatheter Aortic Valve Replacement via Open Versus Percutaneous Approaches

“…Experience from the United States and European trials using sheaths with outer diameters of 8.3 to 9.2 mm (24-26 F) in concert with the first-generation balloon-expandable Edwards Sapien aortic bioprosthesis (Edwards Inc, Irvine, CA) demonstrated a 20% to 30% rate of total vascular complications, which included hematomas, retroperitoneal hemorrhage, and iliofemoral dissection among others. [1][2][3][4][5] These vascular complications were independently associated with mortality. 3 Lower rates of vascular complications have been observed with the use of smaller diameter sheaths in concert with the secondgeneration balloon-expandable Sapien XT valve and the self-expanding CoreValve Revalving System (Medtronic, Inc, Minneapolis, MN).…”